Ocular Therapeutix (OCUL) Short-Term Debt issuances (2023)
Ocular Therapeutix's (OCUL) quarterly Short-Term Debt issuances came in at $2.0 million in Q1 2023.
Ocular Therapeutix (OCUL) Short-Term Debt issuances (2023) Analysis & Trends
Ocular Therapeutix's Short-Term Debt issuances history runs 1 years deep, the most recent figure standing at $2.0 million for Q1 2023.
- On a quarterly basis, Short-Term Debt issuances changed N/A year-over-year to $2.0 million in Q1 2023; TTM through Dec 2023 was $2.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $2.0 million, changed N/A from the prior year.
- Short-Term Debt issuances steadied at $2.0 million in Q1 2023 per OCUL's latest filing.
- Across five years, Short-Term Debt issuances topped out at $2.0 million in Q1 2023 and bottomed at $2.0 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 102,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 58.20 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ocular Therapeutix | 1.94 Bn | 1.94 Bn | 9.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 2.00 Mn |
| Mar 31, 2023 | 2.00 Mn |